Pharma News
-
![Jianxin Biology: Completed the B round of financing to accelerate the phase I clinical study of the pioneering anti-tumor dual antibody products Bis5 and Bis2]( "Jianxin Biology: Completed the B round of financing to accelerate the phase I clinical study of the pioneering anti-tumor dual antibody products Bis5 and Bis2")
Jianxin Biology: Completed the B round of financing to accelerate the phase I clinical study of the pioneering anti-tumor dual antibody products Bis5 and Bis2
2023-03-21New progress in Health Bioharvest.
-
![Heavy! The new indication of the innovative ADC SHR-A1811 is intended to be included in the breakthrough treatment variety]( "Heavy! The new indication of the innovative ADC SHR-A1811 is intended to be included in the breakthrough treatment variety")
Heavy! The new indication of the innovative ADC SHR-A1811 is intended to be included in the breakthrough treatment variety
2023-03-21New progress of ADC research and development of Hengrui
-
![Double Anti selling 546 million yuan! With a total revenue of 1.1 billion yuan in 2022, Kangfang Bio is on the road to a wild ride]( "Double Anti selling 546 million yuan! With a total revenue of 1.1 billion yuan in 2022, Kangfang Bio is on the road to a wild ride")
Double Anti selling 546 million yuan! With a total revenue of 1.1 billion yuan in 2022, Kangfang Bio is on the road to a wild ride
2023-03-21Can you pick the high hanging fruit of double resistance?
-
![Chuangxiang: izokibep HS clinical phase 2b/3 data released]( "Chuangxiang: izokibep HS clinical phase 2b/3 data released")
Chuangxiang: izokibep HS clinical phase 2b/3 data released
2023-03-21Chuang Sound biology overseas progress.
-
![2023 Patent Apocalypse, Generics Get a Boost? Please check out this Top 10 patent cliff]( "2023 Patent Apocalypse, Generics Get a Boost? Please check out this Top 10 patent cliff")
2023 Patent Apocalypse, Generics Get a Boost? Please check out this Top 10 patent cliff
2023-03-21Patent cliff, one happy and one sad.
-
![Pril Pharma: Second contrast agent FDA Approval after iodoparol injection!]( "Pril Pharma: Second contrast agent FDA Approval after iodoparol injection!")
Pril Pharma: Second contrast agent FDA Approval after iodoparol injection!
2023-03-21Gadobul injection was approved by the US FDA.
-
![J. Med. Chem. | new BTK - PROTACs: blood system lymphoma treatment of new ideas]( "J. Med. Chem. | new BTK - PROTACs: blood system lymphoma treatment of new ideas")
J. Med. Chem. | new BTK - PROTACs: blood system lymphoma treatment of new ideas
2023-03-17Pay attention to the most advanced scientific research achievements in the field of protein degradation!
-
![After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?]( "After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?")
After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?
2023-03-17Lilly Solanezumab was a 10-year phase 3 failure.
-
![A share]( "A share")
A share "domestic nine-price HPV vaccine first share" IPO today, how will set off the phenomenon of the new changes in the market?
2023-03-17The guardians of recreation make waves.
-
![Cstone's 2022 earnings: Revenue doubled, with drug sales reaching 364.3 million yuan.]( "Cstone's 2022 earnings: Revenue doubled, with drug sales reaching 364.3 million yuan.")
Cstone's 2022 earnings: Revenue doubled, with drug sales reaching 364.3 million yuan.
2023-03-17Progress in Keystone Pharmaceuticals.
-
![Aike Baifa: Co-developed the world's first COPD drug with Scripps]( "Aike Baifa: Co-developed the world's first COPD drug with Scripps")
Aike Baifa: Co-developed the world's first COPD drug with Scripps
2023-03-17Aike Baifa opens international cooperation.
-
![Rong Chang Bio: A new clinical development of ADC drug RC88 combined with Triprilimab]( "Rong Chang Bio: A new clinical development of ADC drug RC88 combined with Triprilimab")
Rong Chang Bio: A new clinical development of ADC drug RC88 combined with Triprilimab
2023-03-17RC88 combined with triprilimab in the treatment of advanced malignant solid tumors was approved for I/IIa clinical trials.
-
![PCSK9 inhibitors against statins, a new era of fat reduction!]( "PCSK9 inhibitors against statins, a new era of fat reduction!")
PCSK9 inhibitors against statins, a new era of fat reduction!
2023-03-14Will small molecule PCSK9 inhibitors be more competitive?
-
![Nature Chem. Biol. | first PROTAC molecules to STAT5 proteins with high specificity: new in the treatment of chronic myeloid leukemia]( "Nature Chem. Biol. | first PROTAC molecules to STAT5 proteins with high specificity: new in the treatment of chronic myeloid leukemia")
Nature Chem. Biol. | first PROTAC molecules to STAT5 proteins with high specificity: new in the treatment of chronic myeloid leukemia
2023-03-14A new treatment for chronic myeloid leukemia!
-
![Don't pity Silicon Valley banks]( "Don't pity Silicon Valley banks")
Don't pity Silicon Valley banks
2023-03-14How does the butterfly storm of SVB spread to the pharmaceutical industry?
-
![Nuohui Health tore off the]( "Nuohui Health tore off the")
Nuohui Health tore off the "B label", the beginning of China's cancer early screening industry to regain confidence
2023-03-14Young Chinese early screening industry, there is also a lot of room for exploration.
-
![Meifeng Li, the world's leading medical research institution for large animal experiments, has completed A round of financing of 100 million yuan]( "Meifeng Li, the world's leading medical research institution for large animal experiments, has completed A round of financing of 100 million yuan")
Meifeng Li, the world's leading medical research institution for large animal experiments, has completed A round of financing of 100 million yuan
2023-03-14The field of animal testing is gaining new power.
-
![Again, GSK failed to make the case that Mersana's excited HER2 ADC led to death and clinical suspension]( "Again, GSK failed to make the case that Mersana's excited HER2 ADC led to death and clinical suspension")
Again, GSK failed to make the case that Mersana's excited HER2 ADC led to death and clinical suspension
2023-03-14The road is long and blocked
-
![$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics]( "$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics")
$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics
2023-03-10The transaction will enable invoX to invest in and develop F-star's bispecific antibody platform as the backbone of future cancer immunotherapy.
-
![Cypress Biology: more than 100 million yuan of PreA round financing, accelerate the development of new target anti-tumor drugs]( "Cypress Biology: more than 100 million yuan of PreA round financing, accelerate the development of new target anti-tumor drugs")
Cypress Biology: more than 100 million yuan of PreA round financing, accelerate the development of new target anti-tumor drugs
2023-03-10Recent progress in cypress biology.
Hot News
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Forecast of TOP 10 global best-selling drugs in 2021
-
Top 10 Global CDMO Rankings in 2022
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
-
Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial
-
Top 30 best-selling oncology drugs in the world in 2020
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
$157 Million! AstraZeneca Introduces Early-stage covid-19 Drug
-
Taiji Group stirred up 1.5 bn injections and Pfizer and Hawson met their rivals.
-
ECHEMI CPHI Korea Focus 2022.9
Exclusive analysis of China's pharmaceutical market, exploring more digital solutions across the pharmaceuticals.Published in: Sep 28, 2022
